Navigation Links
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Date:3/23/2009

with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Key Events for 2009
2. Micromet Expands Committed Equity Financing Facility to $75 Million
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
7. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
11. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes the ... by the following Product Segments: SPECT Systems (Includes SPECT and ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2013 through ...
(Date:9/16/2014)... -- Chairman and CEO Bernard J. Tyson announced ... the role of interim chief information officer (CIO) for ... "Kaiser Permanente is a recognized leader ... high-quality care and service we provide to our 9.5 ... extensive experience in information technology. I am confident that ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... LLC, a global leader in,non invasive high intensity ... of the Sonablate(R) International HIFU Registry,(SIHR), along with ... Takai,Hospital Supply Co., Ltd., (THS). The SIHR is ... about prostate cancer treatment using HIFU.,It was established ...
... candidates to ... obesity patients, SAN DIEGO, July 9 Orexigen(R) Therapeutics,Inc. ... randomizing patients,in ZB-202, a second Phase IIb clinical trial for ... trial is designed,to build on highly encouraging safety and efficacy ...
Cached Medicine Technology:Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 2Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 2Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 4
(Date:9/17/2014)... FL (PRWEB) September 17, 2014 Fresh ... is pleased to announce its support of The Silver ... seniors understanding of the many benefits of medical marijuana. ... be the first medical marijuana dispensary and ... which is raising funds to launch a statewide radio ...
(Date:9/17/2014)... 2014 Altec Products, Inc., a leader ... their Gold Sponsorship of the 2014 Epicor Prophet 21 ... conference will take place in Dallas, TX at the ... is organized and hosted by the Epicor Prophet 21 ... of members from more than 900 companies in the ...
(Date:9/17/2014)... Kristen Yarker, MSc, RD recently announced the launch of ... to 2 years old who are seeking to provide their ... developing by encouraging healthy eating habits from the get-go. ... How to Transition From Baby Food to Big Kid Food ... Need)” is a new online seminar based on Yarker’s popular ...
(Date:9/17/2014)... Calif. (PRWEB) September 17, 2014 ... monthly interruptions, giving girls of all ages an ... wellness company founded by women, for women, announces ... Uninterrupted® (http://GirlU.com) to relieve the symptoms ... bloating and irritability. , As a lifelong ...
(Date:9/17/2014)... A raucous childhood in an Italian-Polish family ... author Nancy Chovancek’s laughter-filled new book, “Angry Birds and ... short stories that prove the best way to deal ... message of empowerment and resilience, everyone can identify with ... with two books under her belt on the topic ...
Breaking Medicine News(10 mins):Health News:Florida Buds Supports Silver Tour 2Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 2Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 3Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4
... lowered toxicity, lengthened survival , TUESDAY, Jan. 15 (HealthDay ... with six cycles of chemotherapy improves survival in elderly ... Their research was published in the Jan. 15 online ... was expected to appear in the February print issue ...
... is lower in older adolescents and young adults with cancer ... of access to clinical trials nationally for the older age ... Hospital of Pittsburgh of UPMC. , Nationally, cure rates in ... the last 30 years, increasing from 60 percent to approximately ...
... Program Has Already Helped Hundreds of,Uninsured Virginians with ... Launch, NEWPORT NEWS, Va., Jan. 15 ... organization based in,Virginia providing assistance to tens of ... healthcare issues due to financial or insurance denials,- ...
... Jan. 15 Caris Diagnostics, a leading,provider of ... announced the hiring of another nationally renowned,dermatopathologist for ... Caris Diagnostics to support the growing dermatopathology,practice for ... leader in the dermatopathology community for,years, with his ...
... Main offenders are bacterial, and they can strike at any time ... at any time and be caused by any number of different ... and what you can do to protect yourself: , ... the bacteria known as Escherichia coli , or E. coli. ...
... parents with an education platform to start a ... Human Papillomavirus (HPV),cervical cancer preventative vaccines., VAN ... Coalition (NCCC) announces the formation of four new,chapters ... parents,within communities about the cervical cancer HPV preventative ...
Cached Medicine News:Health News:Combo Treatment Best for Elderly Lymphoma Patients 2Health News:Cancer study finds adolescents don't get same access to latest treatments as younger patients 2Health News:Cancer study finds adolescents don't get same access to latest treatments as younger patients 3Health News:Virginia Cares Uninsured Program (VCUP) Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 2Health News:Virginia Cares Uninsured Program (VCUP) Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 3Health News:Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise 2Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 2Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 3Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 4Health News:National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines 2Health News:National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines 3
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This true 8-bit integrated and cooled imaging system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lightin...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
Medicine Products: